Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
Khawaja M. Talha, Stefan D. Anker, Javed Butler
International Journal of Heart Failure (2023) Vol. 5, Iss. 2, pp. 82-82
Open Access | Times Cited: 74

Showing 1-25 of 74 citing articles:

Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits
Joyce Yip, Grace Shu Hui Chiang, I Lee, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 1, pp. 364-364
Open Access | Times Cited: 2
The Role of SGLT2-Inhibitors Across All Stages of Heart Failure and Mechanisms of Early Clinical Benefit: From Prevention to Advanced Heart Failure
Simone Pasquale Crispino, Andrea Segreti, Vincenzo Nafisio, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 608-608
Open Access | Times Cited: 2
Neurohumoral Activation in Heart Failure
Antonis A. Manolis, Theodora A. Manolis, Antonis S. Manolis
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15472-15472
Open Access | Times Cited: 32
SGLT2 Inhibitor Use in Chronic Kidney Disease: Supporting Cardiovascular, Kidney, and Metabolic Health
Magdalena Madero, Glenn M. Chertow, Patrick B. Mark
Kidney Medicine (2024) Vol. 6, Iss. 8, pp. 100851-100851
Open Access | Times Cited: 10
Ketone body levels and its associations with cardiac markers following an acute myocardial infarction: a post hoc analysis of the EMMY trial
Faisal Aziz, Norbert J. Tripolt, Peter N. Pferschy, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 8
SGLT inhibitors for improving Healthspan and lifespan
James H. O’Keefe, Robert Weidling, Evan L. O’Keefe, et al.
Progress in Cardiovascular Diseases (2023) Vol. 81, pp. 2-9
Open Access | Times Cited: 16
Diabetes mellitus and heart disease
Preethi Chandrasekaran, Ralf Weiskirchen
Metabolism and Target Organ Damage (2024) Vol. 4, Iss. 2
Open Access | Times Cited: 4
Increasing Readmissions of HFpEF and the Burden They Cause
Moojun Kim, Chan Joo Lee
International Journal of Heart Failure (2025) Vol. 7, Iss. 1, pp. 30-30
Open Access
The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillation
Yongin Cho, Sung‐Hee Shin, Min-Ae Park, et al.
PLoS ONE (2025) Vol. 20, Iss. 2, pp. e0314454-e0314454
Open Access
Safety and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Older Adults with Variable Disease States: A Meta-analysis of Large Placebo-Controlled Trials
Syeda Ayesha Shah, Hasan Mushahid, Ali Salman, et al.
Drugs & Aging (2025)
Closed Access
Sodium–Glucose Cotransporter 2 Inhibitors as Potential Antioxidant Therapeutic Agents in Cardiovascular and Renal Diseases
Tapan Patel, Hong Zheng, Kaushik P. Patel
Antioxidants (2025) Vol. 14, Iss. 3, pp. 336-336
Open Access
Adoption and Prescribing Practices of Sodium-Glucose Transport Protein-2 (SGLT-2) Inhibitors and Glucagon-Like Peptide-1 (GLP-1) Agonists in Cardiology: A Cross-Sectional Study in Saudi Arabia
Fatema Jamsheer, Anas AlAhmed, Noor H Alshamlan, et al.
Cureus (2025)
Open Access
A Metabolic Health Framework to Interpret Weight Gain Studies in People With Human Immunodeficiency Virus
Giovanni Guaraldi, Jovana Milić
Clinical Infectious Diseases (2025)
Closed Access
Impact of Lifestyle Modifications Along With Pharmacological Treatment of Heart Failure: A Narrative Review
Elizabeth Caroline Palaparthi, Priyanka Kanth, Arockiamary Ignasimuthu, et al.
Cureus (2025)
Open Access
Heart failure outcomes in Sub-Saharan Africa: a scoping review of recent studies conducted after the 2022 AHA/ACC/HFSA guideline release
Djibrilla Siddikatou, Edgar Mandeng Ma Linwa, Valérie Ndobo, et al.
BMC Cardiovascular Disorders (2025) Vol. 25, Iss. 1
Open Access
Cardiovascular and renal outcomes between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors in patients with chronic kidney disease stages 4 and 5: a population-based study
Tien‐Hsing Chen, Te-Hsiung Wang, Ming‐Lung Tsai, et al.
Diabetes Research and Clinical Practice (2025) Vol. 224, pp. 112205-112205
Open Access
Comparative Effectiveness of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors Versus Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) in Heart Failure With Reduced Ejection Fraction: A Systematic Review
Prem Singh, Anusha Sunkara, Fnu Muskan, et al.
Cureus (2025)
Open Access
Obesity and heart failure with preserved ejection fraction: focus on new drugs and future direction in medical treatment
Se-Eun Kim, Byung‐Su Yoo
The Korean Journal of Internal Medicine (2025) Vol. 40, Iss. 3, pp. 357-370
Open Access
Disparities in prescriptions among Danish heart failure patients: a national longitudinal cohort study
Maria Klitgaard Christensen, Vibe Bolvig Hyldgård, Christian Madelaire, et al.
Heart (2025), pp. heartjnl-325562
Closed Access
Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology
Paolo Raggi, Jovana Milić, Marcella Manicardi, et al.
Atherosclerosis (2024) Vol. 392, pp. 117523-117523
Open Access | Times Cited: 3
Roles of cMyBP-C phosphorylation on cardiac contractile dysfunction in db/db mice
Darshini Desai, Akhil Baby, Kalyani Ananthamohan, et al.
Journal of Molecular and Cellular Cardiology Plus (2024) Vol. 8, pp. 100075-100075
Open Access | Times Cited: 3
Heart failure with preserved ejection fraction management: a systematic review of clinical practice guidelines and recommendations
Adil Mahmood, Eamon Dhall, C Primus, et al.
European Heart Journal - Quality of Care and Clinical Outcomes (2024) Vol. 10, Iss. 7, pp. 571-589
Open Access | Times Cited: 3
A Review of Sotagliflozin: The First Dual SGLT-1/2 Inhibitor
Zoya Siddiqui, Niloofar Rasouli, Eliana Felder, et al.
Cardiology in Review (2024)
Closed Access | Times Cited: 3
Pathophysiology of Angiotensin II-Mediated Hypertension, Cardiac Hypertrophy, and Failure: A Perspective from Macrophages
Kelly Carter, Eshan Shah, Jessica Waite, et al.
Cells (2024) Vol. 13, Iss. 23, pp. 2001-2001
Open Access | Times Cited: 3
Dapagliflozin versus empagliflozin in patients with chronic kidney disease
Hilmi Alnsasra, Gal Tsaban, Adam Solomon, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top